HER2-negative Breast Cancer trials recruiting in California
All HER2-negative Breast Cancer trials nationally
9
Recruiting in California
14
Cities with sites
Cities in California
Los Angeles 5San Francisco 4Duarte 2La Jolla 2San Diego 2Beverly Hills 1Davis 1Irvine 1Newport Beach 1Orange 1Oxnard 1Palo Alto 1
Recruiting trials in California
- A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)